Takeaway

• The US FDA approved tremelimumab (an anti-cytotoxic T-lymphocyte-associated antigen 4 monoclonal antibody) for metastatic NSCLC to be given together with another immunotherapy, durvalumab (an anti-programmed cell death-ligand 1 antibody) and platinum-based chemotherapy.
• The patients with NSCLC have no sensitising epidermal growth factor receptor mutation or anaplastic lymphoma kinase genomic tumour alterations.

Why this...